Drug intelligence / Profile preview

NE3789

Development stage: Preclinical
Lead developer: BioVie
Modality: Small Molecules

Overview

NE3789 is a small molecule drug under preclinical development by NeurMedix. It is being investigated for its potential use in the treatment of Alzheimer’s disease. Specific mechanistic details, molecular targets, and pharmacological profile of NE3789 have not been disclosed in public sources as of this date.

Targets

MAPK3 (Mitogen-activated protein kinase 1)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on NE3789.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NE3789.

Explore the full profile